Spina bifida epidemiology and demographics
|
Spina bifida Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Spina bifida epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Spina bifida epidemiology and demographics |
|
Risk calculators and risk factors for Spina bifida epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
- The prevalence of spina bifida is approximately 187 to 890 per 100,000 live births.[1]
Age
- Spina bifida is more commonly observed among preterm newborns.[2]
Gender
- Female newborns are more commonly affected with spina bifida than male newborns.[3]
Race
- Spina bifida usually affects individuals of the Malays and Chinese and Indians race.[1]
Epidemiology and Demographics
Incidence
The incidence of spina bifida is approximately 3.5 per 10,000 live births per year in the U.S.[4][5]
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ 1.0 1.1 Csaba G, Körösi J (1968). "A new antitumour agent: phenazathionium-mustard salt". Neoplasma. 15 (4): 443–5. PMID 5684468.
- ↑ Bannur BB, Purandare GM (February 1969). "Microbial production of L-lysine". Hindustan Antibiot Bull. 11 (3): 191–205. PMID 4898641.
- ↑ Doutre MS, Beylot C, Busquet M, Barberis C, Fauchier JM, Lecastereyres D, Beylot J (April 1986). "[Familial scleroderma of the Thibierge-Weissenbach type]". Rev Rhum Mal Osteoartic (in French). 53 (4): 290–1. PMID 3738390.
- ↑ Bass SW, Triolo AJ, Coon JM (August 1972). "Effect of DDT on the toxicity and metabolism of parathion in mice". Toxicol. Appl. Pharmacol. 22 (4): 684–93. PMID 5045772.
- ↑ Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, Anderson P, Mason CA, Collins JS, Kirby RS, Correa A (December 2010). "Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006". Birth Defects Res. Part A Clin. Mol. Teratol. 88 (12): 1008–16. doi:10.1002/bdra.20735. PMID 20878909.